open access

Vol 10, No 1 (2017)
Research paper
Published online: 2017-04-04
Get Citation

Evaluation of Syphilis Total Ab on the Evolis analyzer (BIO-RAD) for blood donation screening

Ewa Sulkowska, Aneta Kopacz, Dorota Kubicka-Russel, Grzegorz Liszewski, Małgorzata Szabelewska, Agnieszka Karcz, Magdalena Łętowska, Piotr Grabarczyk
Journal of Transfusion Medicine 2017;10(1):1-11.

open access

Vol 10, No 1 (2017)
ORIGINAL PAPERS
Published online: 2017-04-04

Abstract

Background: Syphilis Total Ab BIO-RAD (France) is designed for detection of antibodies to Treponemapallidum antigens in human serum and plasma. Tests are performed in automatic analyzers Evolis (BIORAD).
The aim was to evaluate the advantages of the Syphilis Total Ab BIO-RADtest for blood donor screening in Poland. Specificity, sensitivity, repeatability and reproducibility of S/Co values were evaluated. After 18 months of using the test at the Military Blood Center (WCKiK), the results were analyzed and compared to those obtained with other EIA tests which had been in use for 36 months before the implementation of Syphilis Total Ab BIO-RAD.
Material and methods: Specificity evaluation was performed at the Institute Hematology and Transfusion Medicine (IHiT) on samples collected from 2058 currently screened donors. Assessment of clinical sensitivity was based on study outcome of: 1) seropositive sample panels (confirmed), raw and prepared by dilution of positive archive serum, 2) seroconversion panel (SeraCare), 3) samples reactive in a prospective study performed for assessment of test specificity. Additionally, we analyzed results for 48 940 donations tested with Syphilis Total Ab
BIO-RAD between January 2015 and June 2016 and the results were compared with results for 89.672 donations tested in the period 2012–2014 with Trepanostika TP rec. bioMerieux (France).
Results: Specificity of Syphilis Total Ab BIO-RAD test is equal to 99.9%; repeat reactive (RR) samples with indeterminate confirmation results were considered false reactive. In our own panel studies all samples were found reactive both in the evaluated assay and in reference test (100% compliance). The same number of reactive results was reported for both tests in seroconversion panel studies. Frequency of confirmed RR results in the period 2012–2016 at WCKiK was calculated at 0.0079% (11/138,612 donations). Specificity of Syphilis Ab BIO-RAD was equal to 99.98% as compared to 99.79% reported for the period before test implementation and the positive predictive value of the evaluated test was significantly higher (40% vs. 2.65%, p < 0.05).
Conclusions: The S/Co values for specificity, sensitivity, reproducibility and repeatability of Syphilis Total Ab Test BIO-RAD performed on the analyzer Evolis were found satisfactory. The study outcome demonstrates that the choice of a higher-specificity test (positive predictive values) brings about measurable cost-cutting (smaller number of repeat, verification and control tests performed as well as reduced blood component wastage) and reduction in number of temporarily disqualified donors.

Abstract

Background: Syphilis Total Ab BIO-RAD (France) is designed for detection of antibodies to Treponemapallidum antigens in human serum and plasma. Tests are performed in automatic analyzers Evolis (BIORAD).
The aim was to evaluate the advantages of the Syphilis Total Ab BIO-RADtest for blood donor screening in Poland. Specificity, sensitivity, repeatability and reproducibility of S/Co values were evaluated. After 18 months of using the test at the Military Blood Center (WCKiK), the results were analyzed and compared to those obtained with other EIA tests which had been in use for 36 months before the implementation of Syphilis Total Ab BIO-RAD.
Material and methods: Specificity evaluation was performed at the Institute Hematology and Transfusion Medicine (IHiT) on samples collected from 2058 currently screened donors. Assessment of clinical sensitivity was based on study outcome of: 1) seropositive sample panels (confirmed), raw and prepared by dilution of positive archive serum, 2) seroconversion panel (SeraCare), 3) samples reactive in a prospective study performed for assessment of test specificity. Additionally, we analyzed results for 48 940 donations tested with Syphilis Total Ab
BIO-RAD between January 2015 and June 2016 and the results were compared with results for 89.672 donations tested in the period 2012–2014 with Trepanostika TP rec. bioMerieux (France).
Results: Specificity of Syphilis Total Ab BIO-RAD test is equal to 99.9%; repeat reactive (RR) samples with indeterminate confirmation results were considered false reactive. In our own panel studies all samples were found reactive both in the evaluated assay and in reference test (100% compliance). The same number of reactive results was reported for both tests in seroconversion panel studies. Frequency of confirmed RR results in the period 2012–2016 at WCKiK was calculated at 0.0079% (11/138,612 donations). Specificity of Syphilis Ab BIO-RAD was equal to 99.98% as compared to 99.79% reported for the period before test implementation and the positive predictive value of the evaluated test was significantly higher (40% vs. 2.65%, p < 0.05).
Conclusions: The S/Co values for specificity, sensitivity, reproducibility and repeatability of Syphilis Total Ab Test BIO-RAD performed on the analyzer Evolis were found satisfactory. The study outcome demonstrates that the choice of a higher-specificity test (positive predictive values) brings about measurable cost-cutting (smaller number of repeat, verification and control tests performed as well as reduced blood component wastage) and reduction in number of temporarily disqualified donors.

Get Citation

Keywords

syphilis; treponema pallidum; blood donation screening

About this article
Title

Evaluation of Syphilis Total Ab on the Evolis analyzer (BIO-RAD) for blood donation screening

Journal

Journal of Transfusion Medicine

Issue

Vol 10, No 1 (2017)

Article type

Research paper

Pages

1-11

Published online

2017-04-04

Bibliographic record

Journal of Transfusion Medicine 2017;10(1):1-11.

Keywords

syphilis
treponema pallidum
blood donation screening

Authors

Ewa Sulkowska
Aneta Kopacz
Dorota Kubicka-Russel
Grzegorz Liszewski
Małgorzata Szabelewska
Agnieszka Karcz
Magdalena Łętowska
Piotr Grabarczyk

References (13)
  1. Jakubowicz O. Kiła-realne zagrożenie - cz. I. Nowiny Lekarskie 2009, 78, 5-6. : 335–338.
  2. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections – 2008. Geneva: World Health Organization; 2012, http://www.who.int/reproductivehealth/ publications/rtis/stisestimates/en/index.html.
  3. http://ecdc.europa.eu/en/healthtopics/syphilis/pages/annual-epidemiological-report.aspx 2015
  4. Jakubowicz O. Kiła-realne zagrożenie - cz. II. Nowiny Lekarskie 2010, 79. ; 4: 334–336.
  5. Pawińska A., Diagnostyka kiły 16, 224-230. Czynniki zakaźne istotne w transfuzjologii pod red. Brojer E., Grabarczyk P. Warszawa 2015
  6. Loeffelholz MJ, Binnicker MJ. It is time to use treponema-specific antibody screening tests for diagnosis of syphilis. J Clin Microbiol. 2012; 50(1): 2–6.
  7. Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014; 28(12): 1581–1593.
  8. Medyczne zasady pobierania krwi, oddzielania jej składników i wydawania, obowiązujące w jednostkach organizacyjnych publicznej służby krwi, pod redakcją M.Łętowskiej, wydanie III, Warszawa 2014
  9. Rocznik Statystyczny Rzeczpospolitej Polskiej 2014; 10, 388
  10. Dyrektywa 98/79/WE Parlamentu Europejskiego i Rady z dnia 27 października 1998r. w sprawie wyrobów medycznych używanych do diagnozy in vitro.
  11. Grabarczyk P, van Drimmelen H, Kopacz A, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. Transfusion. 2013; 53(10 Pt 2): 2512–2524.
  12. Rozporządzenia Ministra Zdrowia z dnia 25 marca 2014 r. w sprawie biologicznych czynników chorobotwórczych podlegających zgłoszeniu, wzorów formularzy zgłoszeń dodatnich wyników badań w kierunku biologicznych czynników chorobotwórczych oraz okoliczności dokonywania zgłoszeń (Dz. U. poz. 459).
  13. Lalkhen A. G., McCluskey A. Clinical tests: sensivity and specifity;http://ceaccp.oxfordjournals.org

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl